Welcome to our dedicated page for Renovorx news (Ticker: RNXT), a resource for investors and traders seeking the latest updates and insights on Renovorx stock.
RenovoRx, Inc. reports news on targeted oncology drug delivery, the commercialization of RenovoCath®, and clinical development of its TAMP™ therapy platform. The company is a life-sciences issuer developing localized cancer therapies and commercializing RenovoCath, a patented FDA-cleared drug-delivery device used for temporary vessel occlusion and chemotherapeutic drug infusion.
Recurring updates cover RenovoCath adoption at U.S. cancer centers, intellectual-property protection for the device, financing activity, financial results, and presentations of clinical or pharmacologic data. News also tracks IAG, the investigational intra-arterial gemcitabine product candidate delivered via RenovoCath, including disclosures tied to the TIGeR-PaC trial in locally advanced pancreatic cancer and orphan drug designations for pancreatic and bile duct cancer.
RenovoRx (RNXT) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14, 2026.
Management plans to review record second quarter 2026 revenue of $909,000 from RenovoCath sales, following approximately $1.1 million in 2025, driven by growing demand and repeat orders at high-volume cancer centers. The presentation will cover first commercial use of RenovoCath in a sarcoma patient and an update on the fully enrolled Phase III TIGeR-PaC trial of intra-arterial gemcitabine (IAG) in locally advanced pancreatic cancer, with trial completion expected in 1H 2027 and topline data in 2H 2027. Newly published PK-PD data showed TAMP delivery concentrated chemotherapy at the tumor site, locally extracting about 51% of the drug before it entered the bloodstream, with correlations suggesting improved tumor penetration and potential reduction in systemic exposure.
RenovoRx (Nasdaq: RNXT) reported peer‑reviewed PK/PD data from a sub‑study of its Phase III TIGeR‑PaC trial in Cancer Chemotherapy and Pharmacology, evaluating TAMP‑mediated intra‑arterial gemcitabine (IAG) versus standard intravenous gemcitabine (IVG) in 16 locally advanced pancreatic cancer patients.
The study showed an estimated ~51% local drug extraction at the tumor site and significantly reduced systemic gemcitabine exposure with IAG, alongside a statistically significant correlation between dFdU metabolite levels and reductions in CA 19‑9 tumor marker. RenovoRx achieved full TIGeR‑PaC enrollment in August 2026, targeting trial completion in 1H 2027 and topline data in 2H 2027, and reported approximately $1.1M RenovoCath sales in 2025 and record $909,000 revenue in Q2 2026. RenovoCath with gemcitabine and oxaliplatin has received multiple FDA Orphan Drug Designations.
RenovoRx (Nasdaq: RNXT) announced that Nasdaq has confirmed the company has regained compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The closing bid price of its common stock met or exceeded $1.00 for 10 consecutive business days from August 6–19, 2026.
According to RenovoRx, the prior deficiency notice dated December 31, 2025 is now closed and RNXT continues trading on Nasdaq. Management highlighted recent record second-quarter revenue, growth in active commercial cancer center customers for RenovoCath, first commercial clinical use in a sarcoma patient, and completion of enrollment in the Phase III TIGeR-PaC trial.
RenovoRx (Nasdaq: RNXT) received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Application No. 18/184,620 covering methods and apparatuses for targeted therapeutic delivery for cancer using its RenovoCath® dual-occlusion catheter and TAMP™ platform. The patent, once issued, will expand protection for RenovoCath’s catheter system, including primary and secondary catheters, multiple ports, and expandable occlusion balloons that create a controlled treatment zone for localized drug delivery. With this allowance, RenovoRx’s global intellectual property portfolio totals 20 issued or allowed patents and 13 pending patents. The portfolio supports commercialization of RenovoCath, ongoing Phase III TIGeR-PaC clinical development of intra-arterial gemcitabine (IAG), and potential partnerships and licensing opportunities.
RenovoRx (Nasdaq: RNXT) reported record second quarter 2026 revenue of $909,000, up about 61% sequentially and 115% year over year, with gross margin around 84%. First-half 2026 revenue was about $1.5 million.
According to RenovoRx, active commercial cancer center customers reached 21, with a total commercial funnel of 63 centers. The company raised 2026 revenue guidance to $3.75–$4.25 million, implying approximately 241–286% growth versus 2025. Net loss for the quarter was about $2.9 million, or $0.06 per share, with cash and equivalents of roughly $9.5 million, which the company believes funds operations into the second half of 2027.
RenovoRx reported full enrollment of its Phase III TIGeR-PaC trial, expects completion in the first half of 2027 and topline data in the second half of 2027, and highlighted the first commercial RenovoCath use in sarcoma.
RenovoRx (Nasdaq: RNXT) announced full enrollment of its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer, evaluating intra-arterial gemcitabine (IAG) delivered via the FDA-cleared RenovoCath device using the TAMP™ platform versus standard intravenous gemcitabine plus Abraxane. Patient enrollment closed as of August 7, 2026.
According to the company, the study’s primary endpoint is overall survival, with trial completion expected in the first half of 2027 after 86 events (patient deaths); 78 events had occurred as of August 11, 2026. Initial topline data are anticipated in the second half of 2027. The trial has passed two independent interim analyses (after the 26th event in 2023 and 52nd in 2025) with recommendations to continue. RenovoRx reported approximately $1.1 million in RenovoCath sales in 2025 and a record $563,000 in Q1 2026, and RenovoCath with gemcitabine has Orphan Drug Designation for pancreatic and bile duct cancer.
RenovoRx (Nasdaq: RNXT) reported the first commercial clinical use of RenovoCath for localized chemotherapy delivery in a sarcoma patient at CARTI Cancer Center in Little Rock. Treatment began in late June 2026 and is ongoing, delivering chemotherapy near the tumor rather than via systemic intravenous infusion.
CARTI is also using RenovoCath in pancreatic cancer, illustrating broader physician-driven use across solid tumors within the device’s FDA-cleared indications. RenovoCath is cleared for isolation of blood flow and localized infusion, including chemotherapeutic drug delivery. According to RenovoRx, 2025 RenovoCath sales were approximately $1.1 million, with a record $563,000 in Q1 2026.
The company continues to commercialize its TAMP therapy platform and evaluate its intra-arterial gemcitabine (IAG) combination product in the ongoing Phase III TIGeR-PaC trial, targeting locally advanced pancreatic cancer. RenovoRx anticipates full enrollment in the near term and a final data readout in mid to late 2027. IAG is investigational and not yet approved for sale but has received FDA Orphan Drug Designation with potential market exclusivity upon any future approval.
RenovoRx (Nasdaq: RNXT) will participate in a JonesTrading virtual key opinion leader webinar, “The Evolving Pancreatic Cancer Landscape: The Role of RenovoRx's TAMP Platform and Emerging Clinical Advances,” on Thursday, August 13, 2026 at 1:30 p.m. ET. The event will feature oncology experts Dae Won Kim, MD (Moffitt Cancer Center), Ravi Shridhar, MD, PhD (AdventHealth Cancer Institute), CEO Shaun Bagai, and moderator Justin Walsh of JonesTrading.
Topics include the pancreatic cancer treatment landscape, RenovoRx’s TAMP™ platform and FDA-cleared RenovoCath® device, the ongoing Phase III TIGeR-PaC trial of intra-arterial gemcitabine, and clinical integration of TAMP. Commercial updates will cover RenovoCath’s stand-alone device launch, 2025 sales of about $1.1 million, record Q1 2026 sales of $563,000, and efforts to expand cancer center customers. A replay and webcast access will be available via RenovoRx’s investor relations site.
RenovoRx (Nasdaq: RNXT) will host its second quarter 2026 financial results and business highlights conference call on Wednesday, August 12, 2026, at 4:30 p.m. ET. Management plans to discuss growing revenues from commercial sales of the FDA-cleared RenovoCath drug-delivery device, expanding adoption at high-volume U.S. cancer centers, and repeat orders from existing customers.
The call will also provide an update on the ongoing Phase III TIGeR-PaC trial of intra-arterial gemcitabine via RenovoCath in locally advanced pancreatic cancer, with full enrollment anticipated in the near term and final data expected in mid-to-late 2027. RenovoRx will highlight progress on its TAMP™ therapy platform, including Orphan Drug Designation for oxaliplatin in pancreatic cancer, support for investigator-initiated trials, and additional indication exploration. The event offers dial-in and webcast access, with a replay available until August 26, 2026.
RenovoRx (Nasdaq: RNXT) announced a peer-reviewed case study from Moffitt Cancer Center describing intra-arterial gemcitabine delivery via its TAMP therapy platform using the FDA-cleared RenovoCath catheter in unresectable locally advanced pancreatic cancer.
PET-CT showed a 52% reduction in tumor metabolic activity after eight TAMP procedures, while CT scans showed stable disease, suggesting PET-CT may better monitor response to TAMP-delivered treatment.